- Home
- USGO vs EDIT Comparison
USGO vs EDIT Comparison
Compare USGO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- EDIT
- Stock Information
- Founded
- USGO 2015
- EDIT 2013
- Country
- USGO United States
- EDIT United States
- Employees
- USGO N/A
- EDIT N/A
- Industry
- USGO Precious Metals
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USGO Basic Materials
- EDIT Health Care
- Exchange
- USGO Nasdaq
- EDIT Nasdaq
- Market Cap
- USGO 117.3M
- EDIT 115.5M
- IPO Year
- USGO 2023
- EDIT 2016
- Fundamental
- Price
- USGO $9.06
- EDIT $1.72
- Analyst Decision
- USGO Strong Buy
- EDIT Buy
- Analyst Count
- USGO 1
- EDIT 13
- Target Price
- USGO $26.50
- EDIT $6.73
- AVG Volume (30 Days)
- USGO 19.4K
- EDIT 1.9M
- Earning Date
- USGO 05-14-2025
- EDIT 05-12-2025
- Dividend Yield
- USGO N/A
- EDIT N/A
- EPS Growth
- USGO N/A
- EDIT N/A
- EPS
- USGO N/A
- EDIT N/A
- Revenue
- USGO N/A
- EDIT $35,837,000.00
- Revenue This Year
- USGO N/A
- EDIT N/A
- Revenue Next Year
- USGO N/A
- EDIT N/A
- P/E Ratio
- USGO N/A
- EDIT N/A
- Revenue Growth
- USGO N/A
- EDIT N/A
- 52 Week Low
- USGO $5.00
- EDIT $0.91
- 52 Week High
- USGO $14.46
- EDIT $6.22
- Technical
- Relative Strength Index (RSI)
- USGO 43.02
- EDIT 57.11
- Support Level
- USGO $8.64
- EDIT $1.47
- Resistance Level
- USGO $10.00
- EDIT $1.95
- Average True Range (ATR)
- USGO 0.60
- EDIT 0.17
- MACD
- USGO -0.03
- EDIT 0.03
- Stochastic Oscillator
- USGO 19.63
- EDIT 61.98
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.